Tina Graungaard

Efficacy and safety of fast‐acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52‐week, randomized, treat‐to‐target, phase III trial

C. Mathieu, B. Bode, E. Franek, 2018, Diabetes, obesity & metabolism.

Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis

G. Lip, F. Skjøth, L. Rasmussen, 2012, BMJ : British Medical Journal.

Investigation of Pump Compatibility of Fast-Acting Insulin Aspart in Subjects With Type 1 Diabetes

T. Heise, B. Bode, L. Nosek, 2017, Journal of diabetes science and technology.

A randomized, multicentre trial evaluating the efficacy and safety of fast‐acting insulin aspart in continuous subcutaneous insulin infusion in adults with type 1 diabetes (onset 5)

D. Klonoff, E. Renard, M. Evans, 2019, Diabetes, obesity & metabolism.

Risk of Stroke or Systemic Embolism in Atrial Fibrillation Patients Treated With Warfarin: A Systematic Review and Meta-analysis

L. Rasmussen, G. Lip, I. Albertsen, 2013, Stroke.

Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1)

S. Heller, C. Mathieu, R. Bergenstal, 2017, Diabetes Care.

Improvements in Glycemic Control Achieved by Altering the tmax Setting in the iLet® Bionic Pancreas When Using Fast-Acting Insulin Aspart: A Randomized Trial

F. El-Khatib, S. Russell, E. Damiano, 2021, Diabetes Therapy.